Press Room


    Press Release - June 23, 2003

    Pheromone Sciences Issued U.S. Patent on Pheromone's Sensing and Reporting Technology

    Toronto, Ontario (July 23, 2003) -- Pheromone Sciences Corp (TSX-V: PHS), a developer of fertility prediction medical devices for both human and large animal applications, today announced that the U.S. Patent Office has issued patent No. 6,592,529 covering Pheromone's sensing and reporting technology in the early prediction of ovulation for female mammals, including humans, using innovative measurements of sweat ion concentrations. Fertility prediction and detection is of daily interest to the lives of millions of women across the United States.

    "This patent will serve as a valuable asset as we work through licensing opportunities with potential strategic partners in both the human and large animal marketplaces", remarked Christopher Neuman, President and CEO of Pheromone Sciences. "The patent recognizes the propriety position of Pheromone's unique technology for ovulation detection through the non invasive measurement of sweat ion constituents and demonstrates our ongoing commitment to the development of a comprehensive intellectual property portfolio."

    The patent is also applicable to the Company's veterinary program. Within the North American dairy industry, it is estimated that about 2 million dairy cows are monitored for their ovulation date at any given point in time as a precursor to artificial insemination procedures being provided to these cattle.

    About Pheromone Sciences Corp:

    PHEROMONE SCIENCES is a biotechnology and medical diagnostics & device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

    PHEROMONE SCIENCES has capitalized on its potentially breakthrough sensing and reporting technology initially through the development of two products:

    - Fertilit�©-OVâ�¢ monitor, a non- invasive fertility cycle monitoring device for the medical professional & consumer market which provides up to 4 days advance notice of ovulation and thereby improving the probability and speed of conception. The product is approved for marketing in the USA, Canada and Western Europe and the company is currently in discussions for marketing and sales partnerships to bring this technology to the consumer.

    - The company is currently in feasibility studies that may in the future bring this technology to the dairy industry.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

    INVESTOR CONTACT Lorne Woods 1-(800) 937-3095


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News